While the development of novel risk factors for cardiovascular risk assessment is necessary to improve risk stratification, proving its clinical value on top of traditional risk factors is routinely challenging.^[@r1]-[@r3]^ Besides all the innovative and straightforward biomarker research published in the last decades, only very few markers of cardiovascular risk have shown clinical significance.^[@r4],[@r5]^ Among many of them, cystatin C has emerged some years ago as a candidate for improving cardiovascular risk stratification.

In the *Cardiovascular Health Study* (CHS),^[@r6]^ a community-based and longitudinal study with over 4,600 elderly individuals, cystatin C has shown to predict cardiovascular outcomes. As compared with the lowest quintile, the highest quintile of cystatin C was associated with a significantly increased risk of death from cardiovascular causes (hazard ratio \[HR\] 2.27 \[1.73 to 2.97\]), myocardial infarction (HR 1.48 \[1.08 to 2.02\]), and stroke (HR 1.47 \[1.09 to 1.96\]) after multivariate adjustment. However, cystatin C is typically known as a marker of renal function, being roughly correlated with glomerular filtration rate in early stages of kidney diseases.^[@r7],[@r8]^ Reasonably, since glomerular function is a strong surrogate marker of cardiovascular disease, it suggests an obvious association between cystatin C and cardiovascular outcomes. A mechanism to avoid the impact of this inexorable bias was to study only individuals with normal kidney function. Yet, additional studies have shown inconsistent magnitudes of effect between cystatin C and cardiovascular outcomes.

In that context, Einwoegerer and Domingueti^[@r9]^ in this issue of the *Brazilian Archives of Cardiology* investigated the role of plasma cystatin C levels on the risk of all-cause mortality and other softer endpoints by pooling studies of individuals with normal renal function. Unfortunately, only two studies compared quartiles of cystatin C with multivariate regression analysis, hence providing a sample size that is not too far from the original *Ludwigshafen Risk and Cardiovascular Health* (LURIC) study.^[@r10]^ The meta-analysis suggested a robust association between high levels of cystatin C and the risk of all-cause mortality in individuals with normal renal function (HR 2.28 \[1.70 - 3.05\], p \< 0.001). Heterogeneity among studies was substantial (I^2^ \> 50%) and no sensitivity analysis was provided. Besides the critical limitations in meta-analysis data, authors also provided substantial elements in a systematic review of studies on the same topic.

Although a first step for a candidate biomarker is to show strong association with a clinical outcome, this is not sufficient to prove its complementary clinically usefulness beyond traditional cardiovascular risk factors, such as age, gender, smoking, hypertension, diabetes, hyperlipidemia, obesity and aortic stenosis. A next fundamental step is to show whether cystatin C could improve risk prediction of cardiovascular outcomes in Receiver operating characteristic (ROC) curves models, net reclassification index (NRI) and integrated discrimination index (IDI) compared-to or added-to the Framinghan Heart Risk, ASCVD risk score, or any validated cardiovascular risk scores/engines.^[@r11],[@r12]^

Besides the potential mechanistic link between cystatin C and atherosclerotic disease, this association is unlikely to be causal. By using a Mendelian randomization approach, which takes into account both the genetic association with cystatin C and CVD to triangulate the causal effect, and combining a set of cohorts of over 250,000 individuals with 63,000 cases of cardiovascular events from the *Cystatin C Mendelian Randomization Consortium* no association could be found.^[@r13]^ This finding in no way suggests that we should abandon the use of cystatin C for risk stratification purposes in kidney diseases, but there are two key messages in it: (i) it alerts against the chase of therapeutic strategies that target at lowering plasma cystatin C levels; (ii) it also indicates a low likelihood of association between cystatin C as a surrogate cardiovascular marker on top of classical risk factors. However, the last word in favor or against the use of cystatin C in clinical practice for cardiovascular risk stratification of individuals with normal renal function should be based on studies evaluating detrimental effects of this marker on established risk scores/engines.
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